Table 2.
In vitro activity of antimicrobial agents against Gram-negative ESKAPE pathogens isolated from patients with urinary tract infections.
| Organism (n) | Antimicrobial agent | MIC range (μg/mL) | MIC90 (μg/mL) | % Susceptible | % Intermediate | % Resistant |
|---|---|---|---|---|---|---|
| K. pneumoniae (597) | Amikacin | ≤4 to >32 | 16 | 92.3 | 3.7 | 4.0 |
| Cefepime | ≤0.5 to >32 | >32 | 49.6 | 4.2 | 46.2 | |
| Ceftazidime | ≤0.5 to >32 | >32 | 51.1 | 5.5 | 43.4 | |
| Ceftriaxone | ≤1 to >32 | >32 | 46.1 | 0.2 | 53.8 | |
| Ertapenem | ≤0.03 to >4 | >4 | 75.5 | 1.7 | 22.8 | |
| Imipenem | ≤0.06 to >8 | >8 | 81.4 | 2.4 | 16.3 | |
| Levofloxacin | ≤0.5 to >4 | >4 | 57.3 | 2.5 | 40.2 | |
| Piperacillin-Tazobactam | ≤2 to >64 | >64 | 61.5 | 9.6 | 29.0 | |
| K. pneumoniae, ESBL-positive (278) | Amikacin | ≤4 to >32 | 32 | 87.1 | 6.1 | 6.8 |
| Cefepime | ≤0.5 to >32 | >32 | 7.2 | 7.6 | 85.3 | |
| Ceftazidime | ≤0.5 to >32 | >32 | 11.2 | 10.1 | 78.8 | |
| Ceftriaxone | ≤1 to >32 | >32 | 1.8 | 0.4 | 97.8 | |
| Ertapenem | ≤0.03 to >4 | >4 | 62.6 | 3.6 | 33.8 | |
| Imipenem | ≤0.06 to >8 | >8 | 75.9 | 4.3 | 19.8 | |
| Levofloxacin | ≤0.5 to >4 | >4 | 34.5 | 4.0 | 61.5 | |
| Piperacillin-Tazobactam | ≤2 to >64 | >64 | 37.4 | 17.3 | 45.3 | |
| K. pneumoniae, ESBL-negative (319) | Amikacin | ≤4 to >32 | ≤4 | 96.9 | 1.6 | 1.6 |
| Cefepime | ≤0.5 to >32 | >32 | 86.5 | 1.3 | 12.2 | |
| Ceftazidime | ≤0.5 to >32 | >32 | 85.9 | 1.6 | 12.5 | |
| Ceftriaxone | ≤1 to >32 | >32 | 84.6 | 0.0 | 15.4 | |
| Ertapenem | ≤0.03 to >4 | >4 | 86.8 | 0.0 | 13.2 | |
| Imipenem | ≤0.06 to >8 | >8 | 86.2 | 0.6 | 13.2 | |
| Levofloxacin | ≤0.5 to >4 | >4 | 77.1 | 1.3 | 21.6 | |
| Piperacillin-Tazobactam | ≤2 to >64 | >64 | 82.5 | 2.8 | 14.7 | |
| Enterobacter spp. (165) | Amikacin | ≤4 to >32 | 16 | 92.1 | 3.0 | 4.9 |
| Cefepime | ≤0.5 to >32 | >32 | 68.5 | 3.6 | 27.9 | |
| Ceftazidime | ≤0.5 to >32 | >32 | 60.0 | 4.2 | 35.8 | |
| Ceftriaxone | ≤1 to >32 | >32 | 54.6 | 4.9 | 40.6 | |
| Ertapenem | ≤0.03 to >4 | 4 | 79.4 | 3.0 | 17.6 | |
| Imipenem | 0.12 to >8 | 2 | 86.1 | 6.7 | 7.3 | |
| Levofloxacin | ≤0.5 to >4 | >4 | 76.4 | 1.2 | 22.4 | |
| Piperacillin-Tazobactam | ≤2 to >64 | >64 | 72.1 | 8.5 | 19.4 | |
| P. aeruginosa (165) | Amikacin | ≤4 to >32 | >32 | 75.2 | 1.2 | 23.6 |
| Cefepime | ≤0.5 to >32 | >32 | 61.2 | 7.3 | 31.5 | |
| Ceftazidime | ≤0.5 to >32 | >32 | 62.4 | 7.3 | 30.3 | |
| Imipenem | 0.12 to >8 | >8 | 60.0 | 3.6 | 36.4 | |
| Levofloxacin | ≤0.5 to >4 | >4 | 55.2 | 6.1 | 38.8 | |
| Piperacillin-Tazobactam | ≤2 to >64 | >64 | 60.0 | 15.8 | 24.2 | |
| A. baumannii (43) | Amikacin | ≤4 to >32 | >32 | 16.3 | 25.6 | 58.1 |
| Cefepime | ≤1 to >32 | >32 | 11.6 | 9.3 | 79.1 | |
| Ceftazidime | 2 to >32 | >32 | 18.6 | 0.0 | 81.4 | |
| Ceftriaxone | 8 to >32 | >32 | 11.6 | 7.0 | 81.4 | |
| Imipenem | 0.12 to >8 | >8 | 18.6 | 0.0 | 81.4 | |
| Levofloxacin | ≤0.5 to >4 | >4 | 11.6 | 7.0 | 81.4 | |
| Piperacillin-Tazobactam | ≤2 to >64 | >64 | 18.6 | 2.3 | 79.1 | |